Public and private actors are investing in manufacturing solutions to unlock scalable gene and cell therapy production. ARPA‑H awarded BioCurie up to $9.3 million to build an AI‑driven, data‑centric platform intended to model and standardize viral and nonviral gene‑therapy processes, reducing trial‑and‑error in process development and compressing timelines for scale‑up. Separately, Trenchant BioSystems partnered with Invetech to advance the AutoCell fully automated platform targeting point‑of‑care and decentralized cell‑and‑gene therapy (CGT) manufacturing. Early data show potential to source T cells from whole blood and to run multiple patient batches in parallel, aiming to cut cost‑of‑goods and vein‑to‑vein time. Both efforts reflect industry priority to solve production bottlenecks that limit patient access: BioCurie focuses on digital process optimization and modeling across CDMOs and developers, while Trenchant targets hardware automation to decentralize manufacturing and reduce facility burden. Investors and program teams will monitor validation studies, regulatory acceptance of digital and automated workflows, and partnerships with CDMOs and hospitals to gauge how quickly these platforms can de‑risk clinical supply and support commercialization.